ABBV · News · 20260910N

Product / Drug Pipeline Progress

AbbVie Inc. · 2026-09-10 · Importance 31 · Surprise 42

AbbVie reported positive Phase 3 LUNA results for atogepant (Qulipta) in preventing menstrual migraine. The treatment reduced menstrual-period migraine days by 0.8 days versus placebo and achieved the primary endpoint plus all eight secondary endpoints. Secondary improvements included headache burden, acute medication use, functional disability, and cognitive function, creating a potential new indication in a market with no specifically approved therapies.

Key facts

• AbbVie announced positive Phase 3 LUNA study results for atogepant in preventing menstrual migraine, meeting primary and all eight secondary endpoints and demonstrating a statistically significant reduction in migraine days associated with the menstrual period compared to placebo. source
• In the late-stage study AbbVie's atogepant (brand name Qulipta) resulted in patients taking the drug experiencing 0.8 fewer migraine days on average compared to a placebo group and successfully met its primary goal. source